Ji’an, Jiangxi, China, Feb. 25, 2025 — Universe Pharmaceuticals INC (Nasdaq: UPC), a Chinese pharmaceutical producer and distributor, announced today that it received a notice from Nasdaq on February 19, 2025. The notice stated that the company is late in filing its Annual Report on Form 20-F for the fiscal year ending September 30, 2024. This delay is an additional reason for potential delisting from Nasdaq and violates Nasdaq Listing Rule 5250(c)(1).
The company is currently before a Hearings Panel for not complying with Listing Rule 5550(a)(2). It has until February 26, 2025, to request a suspension of the delisting process while the Hearings Panel makes a decision. The company plans to request this stay and is working to complete and file the overdue Form 20-F.
This announcement complies with Nasdaq Listing Rule 5810(b), which requires immediate disclosure of deficiency notifications.
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, located in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. It focuses on manufacturing, marketing, selling, and distributing traditional Chinese medicine derivatives for the elderly, aiming to improve their physical health during aging and promote overall well-being. The company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements made by other pharmaceutical companies. Currently, the company’s products are sold in 30 provinces in China. More information is available on the company’s website at .
Forward-Looking Statements
This announcement contains forward-looking statements, which are not based on historical facts. These statements involve risks and uncertainties and reflect current expectations and projections regarding future events and financial trends that may affect the company’s financial condition, results of operations, business strategy, and financial needs. These statements can be identified by terms such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or similar expressions. The company is not obligated to update these statements to reflect new events or changes in expectations, except as required by law. While the company believes its expectations are reasonable, it cannot guarantee their accuracy and advises investors that actual results may differ significantly. Investors are encouraged to review other factors that could affect the company’s future results in its registration statement and other filings with the U.S. Securities and Exchange Commission.
Contact:
Ms. Lin Yang,
Chief Financial Officer of Universe Pharmaceuticals INC
